Orthocell Limited

Equities

OCC

AU000000OCC6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:10:30 2024-05-01 pm EDT			5-day change	1st Jan Change
0.385 ^AUD	+1.32%		+2.67%	-6.10%

Apr. 15	Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	MT
Apr. 09	Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	MT

Orthocell welcomes globally recognised nerve surgeons to advisory board

March 30, 2023 at 03:31 pm EDT

(via NewsDirect)

Orthocell Ltd (ASX:OCC) MD Paul Anderson tells Proactive the company has appointed two internationally recognised orthopaedic surgeons specialising in nerve transfer and peripheral nerve repair, Professor Christopher Dy and Professor David Brogan, to the company’s Medical Scientific Advisory Board (MSAB). Professors Dy and Brogan are based at Washington University and Barnes-Jewish Orthopedic Center, one of the US’s leading academic research institutions and hospitals, and have been appointed to assist with clinical development and US market access for Orthocell’s nerve repair medical device.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Orthocell Limited

Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	Apr. 14	MT
Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	Apr. 08	MT
Orthocell Completes First Stage of Remplir US Market Authorization Study	Mar. 24	MT
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Orthocell Completes AU$3.5 Million Share Placement	Feb. 21	MT
Orthocell Submits Regulatory Application for Remplir in Singapore	Feb. 12	MT
Orthocell Limited Announces Resignation of Matthew Callahan from the Board	Jan. 15	CI
Orthocell Limited Appoints Kim Beazley AC as an Independent Non-Executive Director	Jan. 14	CI
Orthocell Completes Chair Transition Process	Dec. 21	MT
Orthocell Limited Announces Changes to its Board	Dec. 21	CI
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023	23-10-24	CI
Orthocell Limited Announces Board Changes	23-10-24	CI
Orthocell Limited Announces Board Changes	23-09-21	CI
Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Orthocell Secures Over AU$3 Million R&D Tax Rebate	23-06-20	MT
Orthocell Appoints Nonexecutive Chair	23-05-29	MT
Orthocell Limited Announces Board Changes	23-05-28	CI
Orthocell Begins Comparator Study for Product Marketing Initiatives	23-04-17	MT
Orthocell Limited Announces Appointments to its Medical and Scientific Advisory Board	23-03-28	CI
Orthocell Limited Appoints Ravi I. Thadhani as Independent Non-Executive Director	23-03-07	CI
Orthocell Announces Company Secretary Changes	23-02-28	CI
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Orthocell's Nerve Repair Product Joins Australian Prosthesis Reimbursement List	22-10-31	MT
Orthocell Says Cell Therapy Effective in Rotator Cuff Injuries	22-09-29	MT
Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients	22-09-28	CI

Chart Orthocell Limited

Duration

Period

More charts

Company Profile

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORTHOCELL LIMITED	-6.10%	51.67M
VERTEX PHARMACEUTICALS INCORPORATED	-1.36%	104B
REGENERON PHARMACEUTICALS, INC.	+5.12%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-13.52%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-11.00%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.73%	14.39B
SAREPTA THERAPEUTICS, INC.	+40.39%	12.37B

Bio Therapeutic Drugs